STVN
Stevanato Group S.p.A.
$21.03
-1.27
(-5.70%)
Mkt Cap
5.74B
Volume
344,022
52W Range
12.89-28
Sector
Healthcare
Beta
0.74
EPS (TTM)
0.56 USD
P/E Ratio
37.81
Revenue (TTM)
1.42B USD
Rev Growth (5Y)
+11.5%
EPS Growth (5Y)
+11.8%
AlphaVal · Fair Value
What we estimate one share is worth
$10.15
Overvalued
strong signal
107.1% above fair value
Modeled from cash flows & growth.
AlphaQuality · Grade
How strong & durable the business is
C+
Stable Earnings Power
58.1 / 100 composite
Steady, predictable earnings power — graded A–F vs. similar companies.
Company Description
Stevanato Group S.p.A. is dedicated to engineering, manufacturing, and distributing integrated solutions for the pharmaceutical and healthcare sectors. Its core offerings span a wide array of products, including containment solutions, drug delivery systems, and medical devices, alongside diagnostic and analytical support. The company also produces specialized machinery for tasks such as visual inspection, assembly, packaging, and glass formation. Established in 1949, the company's main operations are situated in Piombino Dese, Italy, functioning as a subsidiary of Stevanato Holding S.R.L.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 1.14B | 1.10B | 1.09B | 983.68M | 843.92M | 662.04M | 536.54M |
| Net Income | 134.28M | 117.78M | 145.63M | 142.85M | 134.32M | 78.51M | 39.20M |
| EPS | 0.49 | 0.43 | 0.55 | 0.53 | 0.53 | 0.28 | 0.15 |
| Free Cash Flow | 21.44M | (157.79M) | (336.72M) | (139.81M) | 20.16M | 59.65M | (31.33M) |
| FCF / Share | 0.08 | -0.58 | -1.27 | -0.53 | 0.08 | 0.23 | -0.12 |
| Operating CF | 274.79M | 155.78M | 105.21M | 103.31M | 133.34M | 155.66M | 42.57M |
| Total Assets | 2.54B | 2.33B | 2.07B | 1.66B | 1.42B | 967.98M | 882.18M |
| Total Debt | 470.70M | 428.97M | 396.59M | 218.37M | 244.29M | 363.01M | 375.67M |
| Cash & Equiv | 130.54M | 98.27M | 69.60M | 228.74M | 411.04M | 115.60M | 85.39M |
| Book Value | 1.49B | 1.40B | 1.13B | 996.13M | 842.07M | 310.50M | 265.49M |
| Return on Equity | 0.09 | 0.08 | 0.13 | 0.14 | 0.16 | 0.25 | 0.15 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 302.00M | 273.57M | 343.25M | 303.17M | 280.04M | 256.60M | 330.60M | 277.87M | 259.58M | 235.99M | 320.64M | 271.42M |
| Net Income | 23.00M | 28.03M | 47.15M | 36.06M | 29.70M | 26.52M | 48.31M | 30.03M | 20.62M | 18.81M | 45.23M | 37.89M |
| EPS | 0.08 | 0.10 | 0.17 | 0.13 | 0.11 | 0.10 | 0.18 | 0.11 | 0.08 | 0.07 | 0.17 | 0.15 |
| Free Cash Flow | (33.87M) | 4.77M | 4.65M | (1.17M) | (15.36M) | 28.05M | (45.25M) | (110.24M) | (46.47M) | (31.12M) | (76.94M) | (259.78M) |
| FCF / Share | -0.12 | 0.02 | 0.02 | -0.00 | -0.06 | 0.10 | -0.17 | -0.40 | -0.17 | -0.12 | -0.29 | -0.98 |
| Operating CF | 31.86M | 75.49M | 92.46M | 47.22M | 44.91M | 99.84M | 43.63M | 112.14M | 22.30M | 71.59M | 10.19M | 95.02M |
| Total Assets | 2.62B | 2.58B | 2.54B | 2.41B | 2.35B | 2.32B | 2.33B | 2.21B | 2.20B | 2.21B | 2.07B | 1.93B |
| Total Debt | 442.99M | 448.52M | 470.70M | 450.33M | 414.95M | 393.35M | 428.97M | 361.81M | 315.89M | 373.99M | 396.59M | 295.76M |
| Cash & Equiv | 78.64M | 111.67M | 130.54M | 113.30M | 94.17M | 90.72M | 98.27M | 78.00M | 78.10M | 186.33M | 69.60M | 64.82M |
| Book Value | 1.55B | 1.53B | 1.49B | 1.44B | 1.40B | 1.42B | 1.40B | 1.32B | 1.32B | 1.33B | 1.13B | 1.10B |
| Return on Equity | 0.01 | 0.02 | 0.03 | 0.03 | 0.02 | 0.02 | 0.03 | 0.02 | 0.02 | 0.01 | 0.04 | 0.03 |
STVN News
Stevanato Group SpA (STVN) Shares Fall 5.7% -- What GF Score of 87 Tells Investors
Stevanato Group Q2 Earnings Call Highlights
Stevanato Group Q2 Earnings Call Highlights
Is Stevanato (STVN) a Solid Growth Stock? 3 Reasons to Think "Yes"
Stevanato Group S.p.A. (STVN) Q2 2026 Earnings Call Transcript
Stevanato Group (STVN) Q2 Earnings Top Estimates
Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026
Liraglutide Combination Products Incorporating Stevanato Group's Alina® Pen Injector Received Marketing Authorizations in Multiple European Countries
Stevanato Group to Report Second Quarter 2026 Financial Results on August 4, 2026
Stevanato: HVS Momentum Overshadows Engineering Weakness, Offering Compelling Upside